Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Sequencing, and Safety
In routine practice, PHESGO<sup>®</sup> showed substantial neoadjuvant activity, acceptable toxicity, and workflow advantages. Early use of subcutaneous dual HER2 blockade with taxane may enhance pCR and facilitate delivery; prospective validation is warranted.
Authors
- Keiko Yanagihara (ORCID: https://orcid.org/0000-0003-2708-4550)
- Sayuri Kato (ORCID: https://orcid.org/0009-0005-2014-2385)
- Koji Nagata (ORCID: https://orcid.org/0000-0002-4704-0603)
- Miki Tamura (ORCID: https://orcid.org/0000-0003-0763-1174)
- Kentaro Awaji (ORCID: https://orcid.org/0000-0003-3864-5587)
- Takashi Yamakawa (ORCID: https://orcid.org/0000-0002-9528-9198)
- Masato Yoshida
Institutions
- Nippon Medical School (JP)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.3390/curroncol32120658
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05